STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Tang Capital Affiliates Own 13.5M Shares of CMPX, Filing Shows

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital affiliates and Kevin Tang report shared beneficial ownership of 13,496,208 shares of Compass Therapeutics common stock, representing 9.8% of the outstanding class based on 138,282,498 shares outstanding as of April 28, 2025. The filing states no sole voting or dispositive power; all 13,496,208 shares are held with shared voting and shared dispositive power among Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang. The filing certifies the holdings were not acquired to change or influence control of the issuer.

Positive

  • Material disclosure of a 9.8% position (13,496,208 shares) provides transparency to the market
  • Clear identification of all reporting persons and their shared voting and dispositive powers
  • Certification included stating shares were not acquired to change or influence control

Negative

  • None.

Insights

TL;DR: Tang Capital group holds a material 9.8% stake in CMPX with shared voting/dispositive power, a notable ownership position for investors to track.

The filing discloses a significant passive stake equal to 13,496,208 shares, representing 9.8% of the company based on the issuer's reported share count. All voting and dispositive authority is shared across multiple Tang entities and Kevin Tang, with zero sole voting or dispositive power reported. This is a standard Section 13 disclosure identifying a large holder; the statement includes a certification that the shares were not acquired to change control.

TL;DR: Ownership structure shows clustered, shared control across related entities and an individual, requiring clear coordination among reporting parties.

The report documents that voting and disposition rights are exercised jointly by affiliated funds, entities and Kevin Tang. Such shared arrangements are common for investment groups and require coordinated disclosures. The statement explicitly classifies types of reporting persons and provides addresses and organizational jurisdictions for each filer, supporting transparency about who exercises shared authority over the 9.8% position.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang. The percentages used herein are based on 138,282,498 shares of Common Stock outstanding as of April 28, 2025, as set forth in the Issuer's Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on May 8, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G



TANG CAPITAL MANAGEMENT, LLC
Signature:/s/ Kevin Tang
Name/Title:Manager
Date:08/14/2025
KEVIN TANG
Signature:/s/ Kevin Tang
Name/Title:Self
Date:08/14/2025
TANG CAPITAL PARTNERS, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:08/14/2025
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:08/14/2025
TANG CAPITAL PARTNERS III, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:08/14/2025
TANG CAPITAL PARTNERS IV, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:08/14/2025

FAQ

How many Compass Therapeutics (CMPX) shares does Tang Capital report owning?

The filing reports 13,496,208 shares beneficially owned by Tang Capital-related parties.

What percentage of CMPX does the reported position represent?

The reported position represents 9.8% of Compass Therapeutics' common stock based on 138,282,498 shares outstanding as of April 28, 2025.

Do any of the reporting persons have sole voting or dispositive power?

No; the filing states 0 shares of sole voting power and 0 shares of sole dispositive power, and all 13,496,208 shares are held with shared voting and dispositive power.

Which entities and individuals are listed as reporting persons in the Schedule 13G/A?

The filers are Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang.

Does the filing state the shares were acquired to influence control of CMPX?

The certification in the filing states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Compass Therapeutics Inc

NASDAQ:CMPX

CMPX Rankings

CMPX Latest News

CMPX Latest SEC Filings

CMPX Stock Data

983.58M
142.27M
11.42%
62.64%
5.98%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON